Folgen
Robert Shafer
Robert Shafer
Professor of Medicine, Stanford University
Bestätigte E-Mail-Adresse bei stanford.edu - Startseite
Titel
Zitiert von
Zitiert von
Jahr
2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
12522011
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
International HIV Controllers Study
Science 330 (6010), 1551-1557, 2010
11412010
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ...
PloS one 4 (3), e4724, 2009
11352009
2017 update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 24 (4), 132, 2016
11272016
The biological and clinical significance of emerging SARS-CoV-2 variants
K Tao, PL Tzou, J Nouhin, RK Gupta, T de Oliveira, SL Kosakovsky Pond, ...
Nature Reviews Genetics 22 (12), 757-773, 2021
10752021
Human immunodeficiency virus reverse transcriptase and protease sequence database
SY Rhee, MJ Gonzales, R Kantor, BJ Betts, J Ravela, RW Shafer
Nucleic acids research 31 (1), 298-303, 2003
10512003
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection
PM Small, RW Shafer, PC Hopewell, SP Singh, MJ Murphy, ED Desmond, ...
New England Journal of Medicine 328 (16), 1137-1144, 1993
7781993
Web resources for HIV type 1 genotypic-resistance test interpretation
TF Liu, RW Shafer
Clinical infectious diseases 42 (11), 1608-1618, 2006
7512006
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
C Wang, Y Mitsuya, B Gharizadeh, M Ronaghi, RW Shafer
Genome research 17 (8), 1195-1201, 2007
5612007
HIV-1 antiretroviral resistance: scientific principles and clinical applications
MW Tang, RW Shafer
Drugs 72, e1-e25, 2012
5042012
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
GK Robbins, V De Gruttola, RW Shafer, LM Smeaton, SW Snyder, ...
New England Journal of Medicine 349 (24), 2293-2303, 2003
4772003
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
RW Shafer, JM Schapiro
AIDS reviews 10 (2), 67, 2008
4762008
Rationale and uses of a public HIV drug‐resistance database
RW Shafer
The Journal of infectious diseases 194 (Supplement_1), S51-S58, 2006
4742006
Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection
RW Shafer, DS Kim, JP Weiss, JM Quale
Medicine 70 (6), 384-397, 1991
4671991
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
RW Shafer, SY Rhee, D Pillay, V Miller, P Sandstrom, JM Schapiro, ...
Aids 21 (2), 215-223, 2007
4362007
Genotypic testing for human immunodeficiency virus type 1 drug resistance
RW Shafer
Clinical microbiology reviews 15 (2), 247-277, 2002
4362002
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ...
PLoS medicine 2 (4), e112, 2005
3912005
HIV-1 drug resistance and resistance testing
DS Clutter, MR Jordan, S Bertagnolio, RW Shafer
Infection, Genetics and Evolution 46, 292-307, 2016
3752016
Genotypic predictors of human immunodeficiency virus type 1 drug resistance
SY Rhee, J Taylor, G Wadhera, A Ben-Hur, DL Brutlag, RW Shafer
Proceedings of the National Academy of Sciences 103 (46), 17355-17360, 2006
3492006
Update of the drug resistance mutations in HIV-1: March 2013
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ...
Topics in antiviral medicine 21 (1), 6, 2016
3282016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20